AERI Insider Trading Activity and SEC Form 4 Filings
AERI insider trading summary
No open-market insider purchases or sales of Aerie Pharmaceuticals Inc (AERI) have been reported on SEC Form 4 in the past 12 months.
Latest AERI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 11, 2020 | Casey C. Kopczynski | Chief Scientific Officer | Sell | $295K (22,695 @ $13.01) |
| Nov 10, 2020 | Casey C. Kopczynski | Chief Scientific Officer | Sell | $95K (7,305 @ $13.00) |
| May 8, 2020 | Gerald D. Cagle | Director | Sell | $76K (5,000 @ $15.27) |
| Feb 27, 2020 | Foresite Capital Fund IV, L.P. | 10% Owner | Sell | $5.2M (302,776 @ $17.07) |
| Feb 27, 2020 | Foresite Capital Management III, LLC | 10% Owner | Sell | $5.2M (302,776 @ $17.07) |
| Feb 27, 2020 | Foresite Capital Fund III, L.P. | 10% Owner | Sell | $5.2M (302,776 @ $17.07) |
| Feb 27, 2020 | Foresite Capital Fund II, L.P. | 10% Owner | Sell | $7.3M (425,457 @ $17.07) |
| Feb 27, 2020 | Foresite Capital Management II, LLC | 10% Owner | Sell | $5.2M (302,776 @ $17.07) |
| Feb 27, 2020 | Foresite Capital Management II, LLC | 10% Owner | Sell | $7.3M (425,457 @ $17.07) |
| Feb 27, 2020 | James B. Tananbaum | 10% Owner | Sell | $5.2M (302,776 @ $17.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.